Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011.

Fourth quarter 2012 results:

•    Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011
•    GAAP net income for the quarter of $72 million, or $0.53 per diluted share, compared to net income of $12 million, or $0.09 per diluted share, for the fourth quarter of 2011
•    Non-GAAP net income for the quarter of $57 million, or $0.42 per diluted share, compared to $44 million, or $0.35 per diluted share, for the fourth quarter of 2011 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures)
•    Cash flow from operations of $79 million and free cash flow of $62 million for the quarter

Gross margin in the fourth quarter of 2012 was 65.8% compared to 68.2% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangibles, and amortization of inventory revaluation costs, non-GAAP gross margin was 68.5% for the fourth quarter of 2012 compared to 70.2% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2012 were $56.9 million compared to $45.5 million in the fourth quarter of 2011. R&D expenses included $8.0 million and $7.3 million of non-cash stock compensation expense in the fourth quarters of 2012 and 2011, respectively. Excluding these charges and contingent compensation expense, R&D expenses as a percentage of revenue were 15.4% compared to 15.0% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2012 were $79.7 million compared to $60.9 million for the fourth quarter of 2011. SG&A expenses included $14.1 million and $12.7 million of non-cash stock compensation expense in the fourth quarters of 2012 and 2011, respectively. Excluding these charges, contingent compensation, acquired intangible asset amortization, and legal contingencies, SG&A expenses as a percentage of revenue were 19.9% compared to 20.1% in the prior year period.

GAAP net income included the impact of a pre-tax gain of $48.6 million from the sale of the Company's minority ownership interest in deCODE Genetics to Amgen, Inc.

Depreciation and amortization expenses were $18.1 million and capital expenditures were $17.1 million during the fourth quarter of 2012. The Company ended the quarter with $1.35 billion in cash, cash equivalents and short-term investments, compared to $1.19 billion as of January 1, 2012.

Fiscal 2012 results:

•    Revenue of $1.15 billion, a 9% increase over the $1.06 billion reported in fiscal 2011
•    GAAP net income of $151 million, or $1.13 per diluted share, compared to $87 million, or $0.62 per diluted share in fiscal 2011
•    Non-GAAP net income of $210 million, or $1.59 per diluted share, compared to $176 million, or $1.30 per diluted share, in fiscal 2011 (see table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures)

Gross margin for fiscal 2012 was 67.4% compared to 67.2% in fiscal 2011. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangibles, legal contingencies, and amortization of inventory revaluation costs, non-GAAP gross margin was 69.7% for fiscal 2012 compared to 69.0% in fiscal 2011.

R&D expenses for fiscal 2012 were $231.0 million compared to $196.9 million in fiscal 2011. R&D expenses for fiscal 2012 included a one-time impairment charge of $21.4 million related to an in-process research and development asset previously acquired. R&D expenses also included $30.9 million and $32.1 million of non-cash stock compensation expense in fiscal 2012 and 2011, respectively. Excluding these charges and contingent compensation expense, R&D expenses as a percentage of revenue were 15.3% compared to 15.2% in the prior year.

SG&A expenses for fiscal 2012 were $286.0 million compared to $261.8 million in fiscal 2011. SG&A expenses included $55.4 million and $52.3 million of non-cash stock compensation expense in fiscal 2012 and 2011, respectively. Excluding these charges, contingent compensation expense, acquired intangible asset amortization, and legal contingencies, SG&A expenses as a percentage of revenue were 19.5% compared to 19.9% in the prior year.

“We are very pleased with our execution in 2012,” stated Jay Flatley, President and CEO. “We ended the year with a strong performance, and made significant progress on our strategy of growing our clinical business, both organically and through acquisition. We remain optimistic about our growth prospects in 2013 and beyond, in spite of the continuing challenges of the economic environment.”

Highlights since our last earnings release

•    Announced a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities
•    Completed the acquisition of Moleculo Inc., which will enable the introduction of a novel library prep method and analysis algorithm to produce synthetic read lengths up to 10 Kb
•    Previewed a new, ordered array flow cell technology that will provide a significant increase in cluster density and number of reads per flow cell
•    Announced a new kit for the HiSeq® 2500 which is capable of generating up to 300 Gb in rapid mode
•    Presented an updated MiSeq® roadmap with chemistry and software enhancements to deliver 15 Gb of throughput
•    Announced Nextera® Rapid Capture Exome Kits to provide the fastest exome enrichment workflow on both the HiSeq 2500 and MiSeq
•    Launched TruSeq® DNA PCR-Free Kits, a simple, all-inclusive sample prep solution for whole-genome sequencing
•    Announced TruSeq Targeted RNA Kits for mid-plex gene expression profiling and validation
•    Announced that Caris Life Sciences has selected the MiSeq system to support Caris' evidence-based molecular profiling service
•    Announced that VWR International, LLC, will distribute Illumina's qPCR portfolio within the United States
•    Announced winners of the MiSeq grant program to accelerate original research in microbial ecology, neglected disease, and human health
•    Named Dr. Robert S. Epstein to the Board of Directors
•    Announced a favorable ruling in patent litigation against Complete Genomics, Inc.
•    Announced new grant recipients of our Agricultural Greater Good Initiative at the 21st International Plant and Animal Genome Conference
•    Repurchased $25 million of common stock under our previously announced share repurchase program


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Biomed Realty and Illumina Announce New Build-to-Suit Laboratory Building
New building to be located in scientific research park, Granta Park, and will serve as Illumina’s new European headquarters.
Friday, June 26, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina, Merck KGaA and Genea Form the Global Fertility Alliance
Global fertility alliance will identify and work on improvements of fertility-related laboratory processes.
Tuesday, June 09, 2015
Global Fertility Research Alliance
Illumina today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment laboratory.
Monday, June 08, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Berry Genomics NextSeq CN500 Instrument Receives CFDA Premarket Clearance
Products collaboratively developed by Berry Genomics and Illumina Serve Chinese clinical NIPT market.
Wednesday, April 01, 2015
Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Illumina Announces Strategic Collaboration with Merck Serono
Collaboration to expand companion diagnostics for oncology.
Friday, March 13, 2015
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!